Client News

Be The Match BioTherapies® and Kiadis Pharma Announce Strategic Collaboration To Accelerate Patient Access To Haploidentical Stem Cell Therapies

Client News

22.MAY 2019 AT 18:00:00 CET Collaboration will support Phase III clinical trial of cell therapy product ATIR101(TM) for blood cancers MINNEAPOLIS & AMSTERDAM, May 22, 2019 – Be The Match BioTherapies®, an … Continue reading “Be The Match BioTherapies® and Kiadis Pharma Announce Strategic Collaboration To Accelerate Patient Access To Haploidentical Stem Cell Therapies”

By Optimum

Kiadis Submits Response to the European Medicines Agency’s Day 180 Second List of Outstanding Issues

Client News

Amsterdam, The Netherlands, May 22, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has submitted … Continue reading “Kiadis Submits Response to the European Medicines Agency’s Day 180 Second List of Outstanding Issues”

By Optimum

IXICO plc – Half Yearly Report to 31 March 2019

Client News

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces its unaudited interim results for the six months ended 31 March 2019. Highlights Commercial and Operational … Continue reading “IXICO plc – Half Yearly Report to 31 March 2019”

By Optimum

DelSiTech Ltd Receives Significant Funding from the Bill & Melinda Gates Foundation for Developing Long-Acting Injectables

Client News

TURKU, Finland, May 21, 2019 /PRNewswire/ — DelSiTech Ltd, a Finnish drug delivery and drug development company, today announced significant grant funding to support the development of long-acting controlled release formulations for family … Continue reading “DelSiTech Ltd Receives Significant Funding from the Bill & Melinda Gates Foundation for Developing Long-Acting Injectables”

By Optimum

Flexipharm Austrading announces launch of Arsenic Trioxide Phebra (arsenic trioxide 1mg/ml concentrate for solution for infusion)

Client News

Secure supply and first vial presentation of a pivotal drug for acute promyelocytic leukaemia FARNBOROUGH, England, May 20, 2019: Flexipharm Austrading the UK specialty pharmaceutical company focused on supplying the NHS with … Continue reading “Flexipharm Austrading announces launch of Arsenic Trioxide Phebra (arsenic trioxide 1mg/ml concentrate for solution for infusion)”

By Optimum

STORM Therapeutics extends Series A to GBP 30M (USD 38.43M) with new investor, Seroba Life Sciences

Client News

Dr Mark Albertella appointed VP Translational Oncology 20 May 2019, Cambridge, UK: STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, today announced that it … Continue reading “STORM Therapeutics extends Series A to GBP 30M (USD 38.43M) with new investor, Seroba Life Sciences”

By Optimum

Asceneuron appoints experienced CNS clinician Dr Eric Yuen to the Board of Directors

Client News

Seasoned pharma & biotech executive joins the Board of mid-stage clinical company Lausanne, SWITZERLAND and Cambridge, MA, USA, May 20, 2019 – Asceneuron, an emerging leader in the development of … Continue reading “Asceneuron appoints experienced CNS clinician Dr Eric Yuen to the Board of Directors”

By Optimum

ImaginAb Enrolls First Patient in Phase II Clinical Trial at a World-Leading Cancer Center in Los Angeles County

Client News

LOS ANGELES, CA, May 16, 2019 – ImaginAb Inc., a clinical stage immuno-oncology imaging company, announces it has enrolled its first patient for the Phase II clinical trial of its lead … Continue reading “ImaginAb Enrolls First Patient in Phase II Clinical Trial at a World-Leading Cancer Center in Los Angeles County”

By Optimum

Enzyre appoints Dirk Pollet as Chief Executive Officer

Client News

Awarded €2M grant and completes seed financing to develop high-precision point-of-care Hemophilia Biochip device April 30th, 2019 Nijmegen, Netherlands: Enzyre, which is developing breakthrough ambulant diagnostic technology for coagulation testing, … Continue reading “Enzyre appoints Dirk Pollet as Chief Executive Officer”

By Optimum

IXICO plc Trading update for the first half of financial year ending 31 March 2019

Client News

On track to deliver robust revenue growth from £21.2m order book Strong closing cash balance of £7.5m as at 31 March 2019 IXICO plc (AIM: IXI), the data analytics company … Continue reading “IXICO plc Trading update for the first half of financial year ending 31 March 2019”

By Optimum

IXICO announces two new biopharmaceutical contracts

Client News

Providing specialist imaging clinical trials services for rare neurological diseases IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has signed contracts with … Continue reading “IXICO announces two new biopharmaceutical contracts”

By Optimum

ImaginAb to Present at Upcoming Investor and Scientific Conferences in April and May 2019

Client News

LOS ANGELES, 17 April 2019 – ImaginAb Inc., a clinical stage immuno-oncology imaging company, today announces that it is scheduled to present at the following investor and scientific conferences in April … Continue reading “ImaginAb to Present at Upcoming Investor and Scientific Conferences in April and May 2019”

By Optimum

Kiadis to Acquire CytoSen Therapeutics, Inc.

Client News

Transaction creates leader in cell-based cancer immunotherapy, with complementary T-cell and NK-cell platforms focused initially on hematopoietic stem cell transplants (HSCT) CytoSen’s lead NK-cell therapy candidate, CSDT002-NK, is expected to … Continue reading “Kiadis to Acquire CytoSen Therapeutics, Inc.”

By Optimum

Futura Medical Preliminary Results for the year ended 31 December 2018

Client News

Sustained Progress made in 2018 Futura Medical plc (AIM: FUM), the pharmaceutical company developing a portfolio of innovative products for sexual health and pain, based on its proprietary, transdermal DermaSys® … Continue reading “Futura Medical Preliminary Results for the year ended 31 December 2018”

By Optimum

AACR Elects ImaginAb Science Advisory Board Member, Dr. Antoni Ribas, as President-Elect at 2019 Annual Meeting

Client News

LOS ANGELES, 4 April 2019 – ImaginAb Inc., a clinical stage immuno-oncology imaging company, congratulates Dr. Antoni Ribas, Ph.D., member of its Science Advisory Board, on his selection as President-Elect … Continue reading “AACR Elects ImaginAb Science Advisory Board Member, Dr. Antoni Ribas, as President-Elect at 2019 Annual Meeting”

By Optimum

F2G appoints Dr Patrick Vink as Chairman

Client News

F2G appoints Dr Patrick Vink as Chairman Brings successful track record of building and growing global businesses MANCHESTER, UK & VIENNA, AUSTRIA – 8 April 2019 – F2G Ltd, the European … Continue reading “F2G appoints Dr Patrick Vink as Chairman”

By Optimum

Elmar Schnee and Diane Parks proposed as new board members of Calliditas Therapeutics

Client News

Apr 5, 2019 Stockholm, Sweden, April 5, 2019 – The nomination committee of Calliditas Therapeutics AB (NASDAQ Stockholm: CALTX) (“Calliditas”) has proposed that Elmar Schnee and Diane Parks be elected … Continue reading “Elmar Schnee and Diane Parks proposed as new board members of Calliditas Therapeutics”

By Optimum

Neuraxpharm attends 27th European Congress of Psychiatry

Client News

Attendance at key European psychiatry summit underlines commitment to medical community CEO Dr. Jörg-Thomas Dierks to attend psychiatry Congress being held in Warsaw April 5, 2019 Neuraxpharm Group, a leading … Continue reading “Neuraxpharm attends 27th European Congress of Psychiatry”

By Optimum

Neuraxpharm Group Announces Expansion in Eastern Europe with the Launch of Neuraxpharm Polska

Client News

Neuraxpharm Polska to drive growth in significant market Appoints Wojciech Góra as General Manager Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system … Continue reading “Neuraxpharm Group Announces Expansion in Eastern Europe with the Launch of Neuraxpharm Polska”

By Optimum